ArticleDiseases & research2026
Krüppel-like Factor 2 (KLF2) Regulates Autophagy, Mitophagy, Mitochondrial Health, and Function During Foam Cell Formation.
Article in Diseases & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Backgrounds: Foam cell (FC) formation is a hallmark of early atherosclerosis, driven by dysregulated lipid uptake, impaired mitochondrial clearance, and metabolic reprogramming in myeloid cells. However, the precise role of KLF2 in modulating autophagy, mitophagy, and glycolysis during FC formation remains inadequately explored. Methods: This study uncovers the critical regulatory role of Krüppel-like factor 2 (KLF2) during foam cell formation of myeloid cells (RAW264.7) using quantitative real-time PCR, immunocytochemistry, confocal microscopy, and glycolysis stress test methods. Results: Exposure to oxidized low-density lipoprotein (ox-LDL) suppressed autophagy and mitophagy markers in myeloid cells. It also increased glycolytic activity in myeloid cells during FC formation. A well-known chemical suppressor of KLF2, GGPP, further amplified these changes, highlighting the importance of endogenous KLF2 in maintaining mitochondrial health and metabolic functions during formation. To confirm the role of KLF2 in this process, when a chemical inducer of KLF2, GGTI298, was added during FC formation, it restored autophagic and mitophagic machinery, including the expression of Beclin1, LC3B, Parkin, and Pink1, and reversed the abnormal increase in glycolysis during FC formation. Conclusion: These findings demonstrate that KLF2 is a key transcriptional regulator that limits FC formation by preserving mitochondrial health and reducing excessive glycolysis. Furthermore, these results suggest KLF2 could be a target for future development of therapeutics for preventing FC formation, which is an early event in atherosclerosis development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.